Hidehito HORINOUCHI· @HHorinouchi · X·· 3 days agoScore70
Body
🔥PERSEE: Pembrolizumab + chemo vs pembrolizumab monotherapy in PD-L1 ≥50% advanced NSCLC
🆙 @Annals_Oncology #ESMO26
☑Phase 3 RCT (GFPC); N=321; mFU 38.7 mo
🎯mPFS 16.1 vs 6.9 mo (HR 0.56, p<0.001); mOS 50.2 vs 29.9 mo (HR 0.77) — chemo adds significant PFS benefit
💡Grade ≥3 irAEs equal (13% each); tolerable combination profile
🎙Dr. Renaud Descourt & Dr. Chantal Decroisette
#LCSM @OncoAlert @Larvol @IASLC
https://www.annalsofoncology.org/article/S0923-7534(26)06892-4/fulltext
66 views · 2 likes · 2 reposts · 0 replies
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial 🎙️ @decroisette 🔢2614O 🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone 🎯PFS HR 0.56, mPFS 16.1 vs 6.9m 🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo 🎯Grade≥3 TRAEs 53.8% vs 19.3% ☑️NCT04547504 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/272 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
Source: Hidehito HORINOUCHI · x.com